GLP-1s benefit Parkinson’s: Barclays sees biopharma impact

Published on 12 Apr 2024 on Seeking Alpha

Barclays cites implications for the biopharma sector after a mid-stage trial showed that the GLP-1...

Read the rest of the article

Start tracking your investments with Statfolio

Biogen Inc's robust product portfolio and pipeline offer a competitive edge in the neurology and ...

GuruFocus.com via Yahoo Finance 26 Apr 2024

Biogen Inc. (NASDAQ:BIIB) Q1 2024 Earnings Call Transcript April 24, 2024 Biogen Inc. misses on e...

Insider Monkey via Yahoo Finance 25 Apr 2024

Biogen BIIB reported first-quarter 2024 adjusted earnings per share (EPS) of $3.67, beating the Z...

Zacks via Yahoo Finance 24 Apr 2024

For the quarter ended March 2024, Biogen Inc. (BIIB) reported revenue of $2.29 billion, down 7% o...

Zacks via Yahoo Finance 24 Apr 2024

Biogen (BIIB) reports improving uptake for its Alzheimer's therapy Leqembi with its Q1 2024 resul...

Seeking Alpha 24 Apr 2024

gained 5.5% premarket on Wednesday after the company reported first-quarter profit that beat...

Market Watch 24 Apr 2024

Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equ...

Insider Monkey via Yahoo Finance 23 Apr 2024

Wall Street expects a year-over-year increase in earnings on lower revenues when Biogen Inc. (BII...

Zacks via Yahoo Finance 17 Apr 2024

The U.S. government projects that the newly approved Alzheimer's therapy from Biogen (BIIB)/ Eisa...

Seeking Alpha 16 Apr 2024

Expectations for US biopharma companies' first quarter earnings are low given the typical...

Proactive Investors 12 Apr 2024